Fig. 3From: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AMLFirst and second FLT3i exposure in cohort 2 (relapsed/refractory) as single agent and in combinations with cytotoxic chemotherapy or low-intensity treatmentBack to article page